LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 73

Search options

  1. Article ; Online: Diagnosis traps for patients with acquired NLRP3 mutation.

    Cescato, Margaux / Cuisset, Laurence / Le Corre, Laurent / Rodero, Mathieu P / Georgin-Lavialle, Sophie

    European journal of internal medicine

    2024  

    Language English
    Publishing date 2024-03-20
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 1038679-8
    ISSN 1879-0828 ; 0953-6205
    ISSN (online) 1879-0828
    ISSN 0953-6205
    DOI 10.1016/j.ejim.2024.01.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Waldenstrom macroglobulinaemia with AA amyloidosis reveals a B-cell-restricted NLRP2 variant.

    Terré, Alexandre / Buob, David / Cez, Alexandre / Rodero, Mathieu P / Georgin-Lavialle, Sophie

    British journal of haematology

    2024  

    Language English
    Publishing date 2024-03-10
    Publishing country England
    Document type Letter
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.19383
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Heterogeneity and functions of the 13 IFN-α subtypes - lucky for some?

    Moreau, Thomas R J / Bondet, Vincent / Rodero, Mathieu P / Duffy, Darragh

    European journal of immunology

    2023  Volume 53, Issue 8, Page(s) e2250307

    Abstract: Type I IFNs are critical for host responses to viral infection and are also implicated in the pathogenesis of multiple autoimmune diseases. Multiple subtypes exist within the type I IFN family, in particular 13 distinct IFN-α genes, which signal through ... ...

    Abstract Type I IFNs are critical for host responses to viral infection and are also implicated in the pathogenesis of multiple autoimmune diseases. Multiple subtypes exist within the type I IFN family, in particular 13 distinct IFN-α genes, which signal through the same heterodimer receptor that is ubiquitously expressed by mammalian cells. Both evolutionary genetic studies and functional antiviral assays strongly suggest differential functions and activity between the 13 IFN-α subtypes, yet we still lack a clear understanding of these different roles. This review summarizes the evidence from studies describing differential functions of IFN-α subtypes and highlights potential reasons for discrepancies between the reports. We examine both acute and chronic viral infection, as well as autoimmunity, and integrate a more recent awareness of the importance of anti-IFN-α autoantibodies in shaping the type I IFN responses in these different conditions.
    Language English
    Publishing date 2023-06-27
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 120108-6
    ISSN 1521-4141 ; 0014-2980
    ISSN (online) 1521-4141
    ISSN 0014-2980
    DOI 10.1002/eji.202250307
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Osteonecrosis in patients with juvenile dermatomyositis: is it associated with anti-MDA5 autoantibody?

    Bader-Meunier, Brigitte / Breton, Sylvain / Duffy, Darragh / Gitiaux, Cyril / Quartier, Pierre / Lemelle, Irène / Meyer, Alain / Welfringer-Morin, Anne / Frémond, Marie-Louise / Charuel, Jean-Luc / Rodero, Mathieu P / Melki, Isabelle

    Rheumatology (Oxford, England)

    2023  Volume 62, Issue 8, Page(s) e242–e245

    MeSH term(s) Humans ; Dermatomyositis/complications ; Autoantibodies ; Interferon-Induced Helicase, IFIH1 ; Lung Diseases, Interstitial ; Osteonecrosis/complications
    Chemical Substances Autoantibodies ; Interferon-Induced Helicase, IFIH1 (EC 3.6.4.13)
    Language English
    Publishing date 2023-01-02
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keac696
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview.

    Rodero, Mathieu P / Crow, Yanick J

    The Journal of experimental medicine

    2016  Volume 213, Issue 12, Page(s) 2527–2538

    Abstract: Type I interferon is a potent substance. As such, the induction, transmission, and resolution of the type I interferon-mediated immune response are tightly regulated. As defined, the type I interferonopathies represent discrete examples of a disturbance ... ...

    Abstract Type I interferon is a potent substance. As such, the induction, transmission, and resolution of the type I interferon-mediated immune response are tightly regulated. As defined, the type I interferonopathies represent discrete examples of a disturbance of the homeostatic control of this system caused by Mendelian mutations. Considering the complexity of the interferon response, the identification of further monogenic diseases belonging to this disease grouping seems likely, with the recognition of type I interferonopathies becoming of increasing clinical importance as treatment options are developed based on an understanding of disease pathology and innate immune signaling. Definition of the type I interferonopathies indicates that autoinflammation can be both interferon and noninterferon related, and that a primary disturbance of the innate immune system can "spill over" into autoimmunity in some cases. Indeed, that several non-Mendelian disorders, most particularly systemic lupus erythematosus and dermatomyositis, are also characterized by an up-regulation of type I interferon signaling suggests the possibility that insights derived from this work will have relevance to a broader field of clinical medicine.
    MeSH term(s) Animals ; Autoimmunity/immunology ; Humans ; Inflammation/pathology ; Inflammation/therapy ; Interferon Type I/metabolism ; Models, Biological ; Penetrance ; Phenotype
    Chemical Substances Interferon Type I
    Language English
    Publishing date 2016-11-07
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 218343-2
    ISSN 1540-9538 ; 0022-1007
    ISSN (online) 1540-9538
    ISSN 0022-1007
    DOI 10.1084/jem.20161596
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: cGMP-AMP synthase paves the way to autoimmunity.

    Rodero, Mathieu P / Crow, Yanick J

    Proceedings of the National Academy of Sciences of the United States of America

    2015  Volume 112, Issue 42, Page(s) 12903–12904

    MeSH term(s) Animals ; Autoimmune Diseases/enzymology ; DNA/metabolism ; Nucleotidyltransferases/metabolism
    Chemical Substances DNA (9007-49-2) ; Nucleotidyltransferases (EC 2.7.7.-)
    Language English
    Publishing date 2015-10-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 209104-5
    ISSN 1091-6490 ; 0027-8424
    ISSN (online) 1091-6490
    ISSN 0027-8424
    DOI 10.1073/pnas.1517578112
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma.

    Tan, Samuel X / Chong, Sharene / Rowe, Casey / Claeson, Magdalena / Dight, James / Zhou, Chenhao / Rodero, Mathieu P / Malt, Maryrose / Smithers, B Mark / Green, Adele C / Khosrotehrani, Kiarash

    Melanoma research

    2023  Volume 33, Issue 6, Page(s) 506–513

    Abstract: Identifying prognostic biomarkers to predict clinical outcomes in stage I and II cutaneous melanomas could guide the clinical application of adjuvant and neoadjuvant therapies. We aimed to investigate the prognostic value of phosphorylated signal ... ...

    Abstract Identifying prognostic biomarkers to predict clinical outcomes in stage I and II cutaneous melanomas could guide the clinical application of adjuvant and neoadjuvant therapies. We aimed to investigate the prognostic value of phosphorylated signal transducer and activator of transcription 5 (pSTAT5) as a biomarker in early-stage melanoma. This study evaluated all initially staged Ib and II melanoma patients undergoing sentinel node biopsy at a tertiary centre in Brisbane, Australia between 1994 and 2007, with survival data collected from the Queensland Cancer Registry. Primary melanoma tissue from 189 patients was analysed for pSTAT5 level through immunohistochemistry. Cox regression modelling, with adjustment for sex, age, ulceration, anatomical location, and Breslow depth, was applied to determine the association between pSTAT5 detection and melanoma-specific survival. Median duration of follow-up was 7.4 years. High pSTAT5 detection was associated with ulceration and increased tumour thickness. However, multivariate analysis indicated that high pSTAT5 detection was associated with improved melanoma-specific survival (hazard ratio: 0.15, 95% confidence interval: 0.03-0.67) as compared to low pSTAT5 detection. This association persisted when pSTAT5 detection was limited to immune infiltrate or the vasculature, as well as when sentinel node positivity was accounted for. In this cohort, staining for high-pSTAT5 tumours identified a subset of melanoma patients with increased survival outcomes as compared to low-pSTAT5 tumours, despite the former having higher-risk clinicopathological characteristics at diagnosis. pSTAT5 is likely an indicator of local immune activation, and its detection could represent a useful tool to stratify the risk of melanoma progression.
    MeSH term(s) Humans ; Melanoma/pathology ; Skin Neoplasms/pathology ; Lymphatic Metastasis ; Disease-Free Survival ; Sentinel Lymph Node Biopsy ; Prognosis ; Melanoma, Cutaneous Malignant
    Language English
    Publishing date 2023-08-10
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1095779-0
    ISSN 1473-5636 ; 0960-8931
    ISSN (online) 1473-5636
    ISSN 0960-8931
    DOI 10.1097/CMR.0000000000000915
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Polymorphisms in IFIH1: the good and the bad.

    Della Mina, Erika / Rodero, Mathieu P / Crow, Yanick J

    Nature immunology

    2017  Volume 18, Issue 7, Page(s) 708–709

    MeSH term(s) Autoimmunity ; Genetic Predisposition to Disease ; Humans ; Interferon-Induced Helicase, IFIH1 ; Interferons ; Polymorphism, Genetic ; RNA
    Chemical Substances RNA (63231-63-0) ; Interferons (9008-11-1) ; IFIH1 protein, human (EC 3.6.1.-) ; Interferon-Induced Helicase, IFIH1 (EC 3.6.4.13)
    Language English
    Publishing date 2017-06-20
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2016987-5
    ISSN 1529-2916 ; 1529-2908
    ISSN (online) 1529-2916
    ISSN 1529-2908
    DOI 10.1038/ni.3765
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis.

    Bekaddour, Nassima / Smith, Nikaïa / Beitz, Benoit / Llibre, Alba / Dott, Tom / Baudry, Anne / Korganow, Anne-Sophie / Nisole, Sébastien / Mouy, Richard / Breton, Sylvain / Bader-Meunier, Brigitte / Duffy, Darragh / Terrier, Benjamin / Schneider, Benoit / Quartier, Pierre / Rodero, Mathieu P / Herbeuval, Jean-Philippe

    Frontiers in immunology

    2023  Volume 14, Page(s) 1178172

    Abstract: Introduction: Among immune cells, activated monocytes play a detrimental role in chronic and viral-induced inflammatory pathologies, particularly in Juvenile Idiopathic Arthritis (JIA), a childhood rheumatoid arthritis (RA) disease. The uncontrolled ... ...

    Abstract Introduction: Among immune cells, activated monocytes play a detrimental role in chronic and viral-induced inflammatory pathologies, particularly in Juvenile Idiopathic Arthritis (JIA), a childhood rheumatoid arthritis (RA) disease. The uncontrolled activation of monocytes and excessive production of inflammatory factors contribute to the damage of bone-cartilage joints. Despite the moderate beneficial effect of current therapies and clinical trials, there is still a need for alternative strategies targeting monocytes to treat RA.
    Methods: To explore such an alternative strategy, we investigated the effects of targeting the CXCR4 receptor using the histamine analog clobenpropit (CB). Monocytes were isolated from the blood and synovial fluids of JIA patients to assess CB's impact on their production of key inflammatory cytokines. Additionally, we administered daily intraperitoneal CB treatment to arthritic mice to evaluate its effects on circulating inflammatory cytokine levels, immune cell infiltrates, joints erosion, and bone resorption, as indicators of disease progression.
    Results: Our findings demonstrated that CXCR4 targeting with CB significantly inhibited the spontaneous and induced-production of key inflammatory cytokines by monocytes isolated from JIA patients. Furthermore, CB treatment in a mouse model of collagen-induce arthritis resulted in a significant decrease in circulating inflammatory cytokine levels, immune cell infiltrates, joints erosion, and bone resorption, leading to a reduction in disease progression.
    Discussion: In conclusion, targeting CXCR4 with the small amino compound CB shows promise as a therapeutic option for chronic and viral-induced inflammatory diseases, including RA. CB effectively regulated inflammatory cytokine production of monocytes, presenting a potential targeted approach with potential advantages over current therapies. These results warrant further research and clinical trials to explore the full therapeutic potential of targeting CXCR4 with CB-like molecules in the management of various inflammatory diseases.
    MeSH term(s) Animals ; Humans ; Mice ; Arthritis, Juvenile/drug therapy ; Arthritis, Rheumatoid ; Bone Resorption ; Cytokines ; Disease Progression ; Histamine/analogs & derivatives ; Inflammation/drug therapy ; Receptors, CXCR4
    Chemical Substances CXCR4 protein, human ; Cytokines ; Histamine (820484N8I3) ; Receptors, CXCR4
    Language English
    Publishing date 2023-09-26
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1178172
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study.

    Dabbak, Imène / Rodero, Mathieu P / Aeschlimann, Florence A / Authier, François-Jérôme / Bodemer, Christine / Quartier, Pierre / Bondet, Vincent / Charuel, Jean-Luc / Duffy, Darragh / Gitiaux, Cyril / Bader-Meunier, Brigitte

    Rheumatology (Oxford, England)

    2022  Volume 61, Issue 11, Page(s) 4514–4520

    Abstract: ... response, compared with antibody-positive forms (P < 0.01). Requirement for ICU (P = 0.029) and cutaneous ... ulcerations (P = 0.018) were associated with a less favourable muscle response. MTX was stopped due ...

    Abstract Objectives: To assess the efficacy and tolerance of the conventional first-line treatment by MTX and CS in patients with JDM regardless of severity.
    Methods: We conducted a monocentric retrospective study of patients with newly diagnosed JDM treated with MTX and CS from 2012 to 2020. The proportion of clinically inactive disease (CID) within 6 months of MTX initiation was evaluated using both Paediatric Rheumatology International Trials Organisation (PRINTO) criteria (evaluating muscle inactive disease) and DAS (evaluating skin inactive disease). We compared responders and non-responders using univariate analyses.
    Results: Forty-five patients with JDM, out of which 30 (67%) severe JDM, were included. After 6 months of treatment with MTX and CS, complete CID, muscle CID and skin CID were achieved in 14/45 (31%), 19/45 (42%) and 15/45 (33%) patients, respectively. The absence of myositis-specific (MSA) or myositis-associated autoantibodies (MAA) at diagnosis was associated with a better overall, cutaneous and muscular therapeutic response, compared with antibody-positive forms (P < 0.01). Requirement for ICU (P = 0.029) and cutaneous ulcerations (P = 0.018) were associated with a less favourable muscle response. MTX was stopped due to intolerance in six patients (13%) before month 6.
    Conclusions: Conventional first-line treatment with MTX was not efficient in a large subset of JDM patients, especially in patients with MSA-positive forms, and in patients with severe JDM. Larger, multicentre cohorts are required to confirm these data and to identify new predictive biomarkers of MTX response, in order to treat patients with JDM as early as possible with appropriate targeted drugs.
    MeSH term(s) Child ; Humans ; Dermatomyositis/complications ; Methotrexate/therapeutic use ; Retrospective Studies ; Myositis/complications ; Adrenal Cortex Hormones/therapeutic use ; Muscular Diseases/drug therapy
    Chemical Substances Methotrexate (YL5FZ2Y5U1) ; Adrenal Cortex Hormones
    Language English
    Publishing date 2022-02-23
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keac107
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top